Lutetium-177 LNC1004 for advanced thyroid cancer that no longer responds to standard treatments
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a radioactive drug called 177Lu-LNC1004 for people with a type of thyroid cancer that is no longer responding to standard treatments. The drug targets a protein called FAP found on tumor cells, which may help shrink tumors and slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have a type of thyroid cancer that no longer responds to radioactive iodine and standard therapies like TKI drugs, or you have chosen not to take these therapies.
- You are in fairly good overall health (able to care for yourself most days).
- You have at least one tumor that can be measured on a scan.
- Your tumor shows high levels of the FAP protein on a special PET/CT scan.
- Your blood counts and organ function (kidney, liver) are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive treatment (177Lu-CTR-FAPI) that targets a protein on thyroid cancer cells. It's for people whose thyroid cancer has stopped responding to standard treatments, including radioactive iodine and targeted therapies.
This trial tests a new radioactive drug, [177Lu]Lu-XT117, that seeks out and delivers radiation to solid tumors that have a specific marker called FAP. It's for people whose cancer has not responded to other treatments or who have no other options.
This trial tests a new drug that targets tumors with a specific marker you can see on a PET scan. It is for people whose cancer has spread or come back after standard treatments, and it may help shrink tumors or slow their growth.
This trial tests an experimental drug called ST-1898 for people with advanced thyroid cancer that has stopped responding to radioactive iodine treatment and has progressed after at least one targeted therapy. It aims to see if ST-1898 can shrink tumors or slow the disease.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This trial tests a new radioactive drug (Lutetium-177 BL-ARC001) for people with advanced solid tumors, including stomach, bowel, and other cancers. It aims to see if the treatment is safe and how well it works.
Hear when a new Radioiodine Refractory Differentiated Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.